Recombinant Human Interferon α2b Injection
- FOB Price:Get Latest Price >
- Min.Order:1 Vial(s)
- Payment Terms:L/C
Ingredients Recombinant human interferon α2b, excipients: polysorbate 80 and benzyl alcohol.
【Properties】 colorless clear liquid.
1, for the treatment of certain viral diseases, such as chronic viral hepatitis (C and B).
2, for the treatment of certain tumors, such as hair cell leukemia, chronic myeloid leukemia, multiple myeloma, laryngeal papilloma, low to moderate non-Hodgkin's lymphoma, kidney cancer, malignant melanoma.
【Specification】 ① 3 million international units (IU) / 0.3ml / support.
② 5 million international units (IU) / 0.5ml / support. In the case of
Dosage This product is preferred subcutaneous injection, but also intramuscular injection:
1, chronic hepatitis C: Recommended dose of 300 to 5 million IU each time, 3 times a week (every other day injection), 3 to 6 months for a course of treatment, the doctor can also adjust the dose according to the specific circumstances of patients.
2, hair cell leukemia: the recommended dose of 3 million IU each time, 3 times a week (every other day injection). The doctor can adjust the dose according to the patient's specific situation. Usually after 1-2 months after treatment showed efficacy, followed by intermittent treatment, so that long-term remission.
3, chronic myeloid leukemia: the recommended dose by body surface area of 3 million per day IU / ㎡, hemoptysis can be maintained after maintenance treatment, every other day injection 1, the doctor can adjust the dose according to the specific circumstances of patients.
4, chronic hepatitis B: the recommended dose of 300 to 5 million IU, daily or every other day subcutaneous injection of 1 to 3 months for a course of treatment, the doctor can adjust the dose according to the specific circumstances of patients.
5, multiple myeloma: in the chemotherapy part or complete remission, 3 million IU 3 times a week until the better.
6, laryngeal papilloma: the recommended dose by body surface area of 300 million IU / ㎡, subcutaneous injection, 3 times a week (every other day), in the surgical (laser) resection of tumor tissue after the start of administration. According to the patient's tolerance to the goods to adjust the dose. Treatment response requires more than 6 months of treatment.
7, low-grade non-Hodgkin's lymphoma: as induction or maintenance therapy, the recommended dose of 300 to 5 million IU / ㎡, subcutaneous or intramuscular injection every other day 3 times a week. According to the patient's tolerance, as appropriate, the dose increased weekly to the maximum tolerance, 8 to 12 weeks for a course of treatment. If the condition does not occur or the intolerant reaction is severe, the dose should be treated for at least 12 months. The doctor can adjust the dose according to the specific circumstances of the patient.
8, renal cell carcinoma: the recommended dose of subcutaneous or intramuscular injection of 300 to 10 million IU, 3 times a week, combined with chemotherapy drugs.
9, malignant melanoma: the recommended dose of 600 million IU each intramuscular injection, 3 times a week, combined with chemotherapy drugs.
1, the use of this product the most common adverse reactions are fever, chills, fatigue, headache, muscle pain, joint pain, anorexia and other flu-like symptoms, plus heat analgesics (paracetamol, etc.) can reduce or eliminate these symptoms, These symptoms can also slow down as medication continues or adjusts the dose.
2, the use of this product common hematological indicators abnormal white blood cells, thrombocytopenia and increased transaminase.
See JIrong shot 20123, the use of this product in the event of an allergic reaction, should immediately stop the medication, and give appropriate treatment.
4, the goods dose of ≥ 600 million IU patients may be severe adverse reactions, need to strengthen the monitoring. The following table shows the adverse effects of clinical trials in 1169 patients in foreign countries (Cuba)
5, the literature reported that α-interferon other adverse reactions include: perception damage, mental disorders, dizziness, motor disorders, paresthesia, anxiety, tension, a transient rash; and rare thigh cramps, constipation, insomnia, herpes, Rash, urticaria, hot flashes, epistaxis, stomatitis, paralytic colic, coagulopathy (prothrombin time and prolonged prothrombin activity), irritability, cough, boil and vision Abnormalities; there are rare orthostatic hypotension, skin erythema, indigestion, purpura, dyspnea, injection site reaction and inflammation, eye movement paralysis, nasal congestion, bloating, increased saliva, hyperglycemia and ulcerative stomatitis.